Next generation predictive biomarkers for immune checkpoint inhibition
Authors:
- 21 November 2016
- journal article
- review article
- Published by Springer Nature in Cancer and Metastasis Reviews
- Vol. 36 (1) , 179-190
Abstract
With the advent of targeted therapies, there has been a revolution in the treatment of cancer across multiple histologies. Immune checkpoint blockade has made it possible to take advantage of receptor-ligand interactions between immune and tumor cells in a wide spectrum of malignancies. Toxicity in healthy tissue, however, can limit our use of these agents. Immune checkpoint blockade has been approved in advanced melanoma, renal cell cancer, non-small cell lung cancer, relapsed refractory Hodgkin’s lymphoma, and urothelial cancer. Though FDA-approved indications for use of some of these novel agents depend on current protein-based programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) assays, detection methods come with several caveats. Additional predictive tools must be interrogated to discern responders from non-responders. Some of these include measurement of microsatellite instability, PD-L1 amplification, cluster of differentiation 8 (CD8) infiltrate density, and tumor mutational burden. This review serves to synthesize biomarker detection at the DNA, RNA, and protein level to more accurately forecast benefit from these novel agents.Keywords
This publication has 59 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Circulating microRNA-21 as noninvasive predictive biomarker for response in cancer immunotherapyMedical Hypotheses, 2013
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- Serum microRNAs as non-invasive biomarkers for cancerMolecular Cancer, 2010
- Pitfalls in TCR gene clonality testing: teaching casesJournal of Hematopathology, 2008
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic FactorsNeoplasia, 2006
- Systematic Review of Microsatellite Instability and Colorectal Cancer PrognosisJournal of Clinical Oncology, 2005
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002